Literature DB >> 22117059

Inhibition of phosphorylation of na+,k+-ATPase by mutations causing familial hemiplegic migraine.

Vivien Rodacker Schack1, Rikke Holm, Bente Vilsen.   

Abstract

The neurological disorder familial hemiplegic migraine type II (FHM2) is caused by mutations in the α2-isoform of the Na(+),K(+)-ATPase. We have studied the partial reaction steps of the Na(+),K(+)-pump cycle in nine FHM2 mutants retaining overall activity at a level still compatible with cell growth. Although it is believed that the pathophysiology of FHM2 results from reduced extracellular K(+) clearance and/or changes in Na(+) gradient-dependent transport processes in neuroglia, a reduced affinity for K(+) or Na(+) is not a general finding with the FHM2 mutants. Six of the FHM2 mutations markedly affect the maximal rate of phosphorylation from ATP leading to inhibition by intracellular K(+), thereby likely compromising pump function under physiological conditions. In mutants R593W, V628M, and M731T, the defective phosphorylation is caused by local perturbations within the Rossmann fold, possibly interfering with the bending of the P-domain during phosphoryl transfer. In mutants V138A, T345A, and R834Q, long range effects reaching from as far away as the M2 transmembrane helix perturb the function of the catalytic site. Mutant E700K exhibits a reduced rate of E(2)P dephosphorylation without effect on phosphorylation from ATP. An extremely reduced vanadate affinity of this mutant indicates that the slow dephosphorylation reflects a destabilization of the phosphoryl transition state. This seems to be caused by insertion of the lysine between two other positively charged residues of the Rossmann fold. In mutants R202Q and T263M, effects on the A-domain structure are responsible for a reduced rate of the E(1)P to E(2)P transition.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22117059      PMCID: PMC3265897          DOI: 10.1074/jbc.M111.323022

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

1.  A novel mutation in the ATP1A2 gene causes alternating hemiplegia of childhood.

Authors:  M T Bassi; N Bresolin; A Tonelli; K Nazos; F Crippa; C Baschirotto; C Zucca; A Bersano; D Dolcetta; F M Boneschi; V Barone; G Casari
Journal:  J Med Genet       Date:  2004-08       Impact factor: 6.318

2.  Rare missense variants in ATP1A2 in families with clustering of common forms of migraine.

Authors:  Unda Todt; Martin Dichgans; Karin Jurkat-Rott; Axel Heinze; Giovanni Zifarelli; Jan B Koenderink; Ingrid Goebel; Vera Zumbroich; Anne Stiller; Alfredo Ramirez; Thomas Friedrich; Hartmut Göbel; Christian Kubisch
Journal:  Hum Mutat       Date:  2005-10       Impact factor: 4.878

3.  ATP1A2 mutations in 11 families with familial hemiplegic migraine.

Authors:  Florence Riant; Maurizio De Fusco; Paolo Aridon; Anne Ducros; Claire Ploton; Florence Marchelli; Jacqueline Maciazek; Marie Germaine Bousser; Giorgio Casari; Elisabeth Tournier-Lasserve
Journal:  Hum Mutat       Date:  2005-09       Impact factor: 4.878

4.  Prolonged hemiplegic episodes in children due to mutations in ATP1A2.

Authors:  J C Jen; A Klein; E Boltshauser; M S Cartwright; E S Roach; H Mamsa; R W Baloh
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-05       Impact factor: 10.154

5.  Recurrent ATP1A2 mutations in Portuguese families with familial hemiplegic migraine.

Authors:  Maria-José Castro; Anine H Stam; Carolina Lemos; José Barros; Raquel G Gouveia; Isabel Pavão Martins; Jan B Koenderink; Kaate R J Vanmolkot; Alexandre P Mendes; Rune R Frants; Michel D Ferrari; Jorge Sequeiros; José M Pereira-Monteiro; Arn M J M van den Maagdenberg
Journal:  J Hum Genet       Date:  2007-10-19       Impact factor: 3.172

6.  Two de novo mutations in the Na,K-ATPase gene ATP1A2 associated with pure familial hemiplegic migraine.

Authors:  Kaate R J Vanmolkot; Esther E Kors; Ulku Turk; Dylsad Turkdogan; Antoine Keyser; Ludo A M Broos; Sima Kheradmand Kia; Jeroen J M W van den Heuvel; David F Black; Joost Haan; Rune R Frants; Virginia Barone; Michel D Ferrari; Giorgio Casari; Jan B Koenderink; Arn M J M van den Maagdenberg
Journal:  Eur J Hum Genet       Date:  2006-05       Impact factor: 4.246

7.  Functional consequences of alterations to Pro328 and Leu332 located in the 4th transmembrane segment of the alpha-subunit of the rat kidney Na+,K(+)-ATPase.

Authors:  B Vilsen
Journal:  FEBS Lett       Date:  1992-12-21       Impact factor: 4.124

8.  Importance of Leu99 in transmembrane segment M1 of the Na+, K+ -ATPase in the binding and occlusion of K+.

Authors:  Anja Pernille Einholm; Jens Peter Andersen; Bente Vilsen
Journal:  J Biol Chem       Date:  2007-06-06       Impact factor: 5.157

9.  A novel ATP1A2 mutation in a family with FHM type II.

Authors:  F Pierelli; G S Grieco; F Pauri; C Pirro; G Fiermonte; A Ambrosini; A Costa; M G Buzzi; M Valoppi; C Caltagirone; G Nappi; F M Santorelli
Journal:  Cephalalgia       Date:  2006-03       Impact factor: 6.292

10.  Haploinsufficiency of ATP1A2 encoding the Na+/K+ pump alpha2 subunit associated with familial hemiplegic migraine type 2.

Authors:  Maurizio De Fusco; Roberto Marconi; Laura Silvestri; Luigia Atorino; Luca Rampoldi; Letterio Morgante; Andrea Ballabio; Paolo Aridon; Giorgio Casari
Journal:  Nat Genet       Date:  2003-01-21       Impact factor: 38.330

View more
  9 in total

Review 1.  Novel role of ouabain as a cystogenic factor in autosomal dominant polycystic kidney disease.

Authors:  Gustavo Blanco; Darren P Wallace
Journal:  Am J Physiol Renal Physiol       Date:  2013-06-12

2.  Crystal structure of a Na+-bound Na+,K+-ATPase preceding the E1P state.

Authors:  Ryuta Kanai; Haruo Ogawa; Bente Vilsen; Flemming Cornelius; Chikashi Toyoshima
Journal:  Nature       Date:  2013-10-02       Impact factor: 49.962

3.  Expression of mutant α1 Na/K-ATPase defective in conformational transition attenuates Src-mediated signal transduction.

Authors:  Qiqi Ye; Fangfang Lai; Moumita Banerjee; Qiming Duan; Zhichuan Li; Shuyi Si; Zijian Xie
Journal:  J Biol Chem       Date:  2013-01-03       Impact factor: 5.157

4.  Relationship between intracellular Na+ concentration and reduced Na+ affinity in Na+,K+-ATPase mutants causing neurological disease.

Authors:  Mads S Toustrup-Jensen; Anja P Einholm; Vivien R Schack; Hang N Nielsen; Rikke Holm; María-Jesús Sobrido; Jens P Andersen; Torben Clausen; Bente Vilsen
Journal:  J Biol Chem       Date:  2013-12-19       Impact factor: 5.157

Review 5.  Cellular function and pathological role of ATP13A2 and related P-type transport ATPases in Parkinson's disease and other neurological disorders.

Authors:  Sarah van Veen; Danny M Sørensen; Tine Holemans; Henrik W Holen; Michael G Palmgren; Peter Vangheluwe
Journal:  Front Mol Neurosci       Date:  2014-05-27       Impact factor: 5.639

6.  Defective glutamate and K+ clearance by cortical astrocytes in familial hemiplegic migraine type 2.

Authors:  Clizia Capuani; Marcello Melone; Angelita Tottene; Luca Bragina; Giovanna Crivellaro; Mirko Santello; Giorgio Casari; Fiorenzo Conti; Daniela Pietrobon
Journal:  EMBO Mol Med       Date:  2016-08-01       Impact factor: 12.137

7.  Gene Network Dysregulation in the Trigeminal Ganglia and Nucleus Accumbens of a Model of Chronic Migraine-Associated Hyperalgesia.

Authors:  Hyeonsoo Jeong; Laura S Moye; Bruce R Southey; Alvaro G Hernandez; Isaac Dripps; Elena V Romanova; Stanislav S Rubakhin; Jonathan V Sweedler; Amynah A Pradhan; Sandra L Rodriguez-Zas
Journal:  Front Syst Neurosci       Date:  2018-12-18

Review 8.  Managing Brain Extracellular K(+) during Neuronal Activity: The Physiological Role of the Na(+)/K(+)-ATPase Subunit Isoforms.

Authors:  Brian Roland Larsen; Anca Stoica; Nanna MacAulay
Journal:  Front Physiol       Date:  2016-04-22       Impact factor: 4.566

Review 9.  ATP1A2 Mutations in Migraine: Seeing through the Facets of an Ion Pump onto the Neurobiology of Disease.

Authors:  Thomas Friedrich; Neslihan N Tavraz; Cornelia Junghans
Journal:  Front Physiol       Date:  2016-06-21       Impact factor: 4.566

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.